Evidence Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2021; 12(2): 61-68
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.61
New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging
Celeste Manfredi, Esaú Fernández-Pascual, Estefanía Linares-Espinós, Felipe Couñago, Juan Ignacio Martínez-Salamanca
Celeste Manfredi, Department of Woman, Child and General and Specialized Surgery, Urology Unit, University of Campania “Luigi Vanvitelli”, Naples 81110, Italy
Esaú Fernández-Pascual, Estefanía Linares-Espinós, Department of Urology, Hospital Universitario La Paz, Madrid 28046, Spain
Esaú Fernández-Pascual, Estefanía Linares-Espinós, Juan Ignacio Martínez-Salamanca, LYX Institute of Urology, Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcón 28223, Madrid, Spain
Felipe Couñago, Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón 28223, Madrid, Spain
Juan Ignacio Martínez-Salamanca, Department of Urology, Hospital Universitario Puerta Hierro-Majadahonda, Majadahonda 28222, Madrid, Spain
Author contributions: Martínez-Salamanca JI contributed with conception, critical revision, and final approval of the manuscript; Manfredi C contributed with literature review and drafting of the manuscript; Fernández-Pascual E, Linares-Espinós E, and Couñago F equally contributed with editing and critical revision of the manuscript.
Conflict-of-interest statement: The authors declare no potential conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juan Ignacio Martínez-Salamanca, MD, PhD, Associate Professor, Department of Urology, Hospital Universitario Puerta Hierro-Majadahonda, Calle Manuel de Falla 1, Majadahonda 28222, Madrid, Spain. jims09@me.com
Received: October 10, 2020
Peer-review started: October 10, 2020
First decision: November 12, 2020
Revised: November 16, 2020
Accepted: January 21, 2021
Article in press: January 21, 2021
Published online: February 24, 2021
Core Tip

Core Tip: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging can be an effective imaging modality for detecting primary and recurrent prostate cancer, besides it seems to provide accurate local staging and restaging. Multiparametric magnetic resonance imaging is considered the standard imaging modality in the context of focal therapy; however, the diagnostic performance of prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging make it an excellent candidate as a technique of choice in this setting.